Maze Therapeutics (NASDAQ:MAZE – Get Free Report) released its earnings results on Monday. The company reported ($18.32) EPS for the quarter, missing the consensus estimate of ($7.60) by ($10.72), Zacks reports.
Maze Therapeutics Trading Down 10.1 %
Shares of MAZE opened at $9.90 on Wednesday. Maze Therapeutics has a 12-month low of $9.49 and a 12-month high of $17.00.
Analyst Ratings Changes
Several research firms have issued reports on MAZE. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 25th. Guggenheim started coverage on Maze Therapeutics in a report on Tuesday, February 25th. They issued a “buy” rating and a $19.00 price target for the company. Leerink Partners began coverage on Maze Therapeutics in a research note on Tuesday, February 25th. They set an “outperform” rating and a $28.00 price objective on the stock. Leerink Partnrs upgraded Maze Therapeutics to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research note on Tuesday, February 25th. They set an “overweight” rating and a $30.00 price target on the stock. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $25.67.
About Maze Therapeutics
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Stories
- Five stocks we like better than Maze Therapeutics
- How to Profit From Value Investing
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Calculate Retirement Income: MarketBeat’s Calculator
- The 3 Most Talked About Investments on WallStreetBets Right Now
- What is diluted earnings per share (Diluted EPS)?
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
